Abstract
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.
Original language | English |
---|---|
Pages (from-to) | 609-615 |
Number of pages | 7 |
Journal | Nature |
Volume | 474 |
Issue number | 7353 |
DOIs | |
State | Published - Jun 30 2011 |
Keywords
- Aged
- Carcinoma/genetics
- DNA Methylation
- Female
- Gene Dosage
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Genomics
- Humans
- MicroRNAs/metabolism
- Middle Aged
- Mutation/genetics
- Ovarian Neoplasms/genetics
- RNA, Messenger/metabolism
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Integrated genomic analyses of ovarian carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature, Vol. 474, No. 7353, 30.06.2011, p. 609-615.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Integrated genomic analyses of ovarian carcinoma
AU - Bell, D.
AU - Berchuck, A.
AU - Birrer, M.
AU - Chien, J.
AU - Cramer, D. W.
AU - Dao, F.
AU - Dhir, R.
AU - Disaia, P.
AU - Gabra, H.
AU - Glenn, P.
AU - Godwin, A. K.
AU - Gross, J.
AU - Hartmann, L.
AU - Huang, M.
AU - Huntsman, D. G.
AU - Iacocca, M.
AU - Imielinski, M.
AU - Kalloger, S.
AU - Karlan, B. Y.
AU - Levine, D. A.
AU - Mills, G. B.
AU - Morrison, C.
AU - Mutch, D.
AU - Olvera, N.
AU - Orsulic, S.
AU - Park, K.
AU - Petrelli, N.
AU - Rabeno, B.
AU - Rader, J. S.
AU - Sikic, B. I.
AU - Smith-Mccune, K.
AU - Sood, A. K.
AU - Bowtell, D.
AU - Penny, R.
AU - Testa, J. R.
AU - Chang, K.
AU - Dinh, H. H.
AU - Drummond, J. A.
AU - Fowler, G.
AU - Gunaratne, P.
AU - Hawes, A. C.
AU - Kovar, C. L.
AU - Lewis, L. R.
AU - Morgan, M. B.
AU - Newsham, I. F.
AU - Santibanez, J.
AU - Reid, J. G.
AU - Trevino, L. R.
AU - Wu, Y. Q.
AU - Wang, M.
AU - Muzny, D. M.
AU - Wheeler, D. A.
AU - Gibbs, R. A.
AU - Getz, G.
AU - Lawrence, M. S.
AU - Cibulskis, K.
AU - Sivachenko, A. Y.
AU - Sougnez, C.
AU - Voet, D.
AU - Wilkinson, J.
AU - Bloom, T.
AU - Ardlie, K.
AU - Fennell, T.
AU - Baldwin, J.
AU - Gabriel, S.
AU - Lander, E. S.
AU - Ding, L.
AU - Fulton, R. S.
AU - Koboldt, D. C.
AU - McLellan, M. D.
AU - Wylie, T.
AU - Walker, J.
AU - O'Laughlin, M.
AU - Dooling, D. J.
AU - Fulton, L.
AU - Abbott, R.
AU - Dees, N. D.
AU - Zhang, Q.
AU - Kandoth, C.
AU - Wendl, M.
AU - Schierding, W.
AU - Shen, D.
AU - Harris, C. C.
AU - Schmidt, H.
AU - Kalicki, J.
AU - Delehaunty, K. D.
AU - Fronick, C. C.
AU - Demeter, R.
AU - Cook, L.
AU - Wallis, J. W.
AU - Lin, L.
AU - Magrini, V. J.
AU - Hodges, J. S.
AU - Eldred, J. M.
AU - Smith, S. M.
AU - Pohl, C. S.
AU - Vandin, F.
AU - Raphael, B. J.
AU - Weinstock, G. M.
AU - Mardis, E. R.
AU - Wilson, R. K.
AU - Meyerson, M.
AU - Winckler, W.
AU - Verhaak, R. G.W.
AU - Carter, S. L.
AU - Mermel, C. H.
AU - Saksena, G.
AU - Nguyen, H.
AU - Onofrio, R. C.
AU - Hubbard, D.
AU - Gupta, S.
AU - Crenshaw, A.
AU - Ramos, A. H.
AU - Chin, L.
AU - Protopopov, A.
AU - Zhang, Jinghui
AU - Kim, T. M.
AU - Perna, I.
AU - Xiao, Y.
AU - Zhang, H.
AU - Ren, G.
AU - Sathiamoorthy, N.
AU - Park, R. W.
AU - Lee, E.
AU - Park, P. J.
AU - Kucherlapati, R.
AU - Absher, D. M.
AU - Waite, L.
AU - Sherlock, G.
AU - Brooks, J. D.
AU - Li, J. Z.
AU - Xu, J.
AU - Myers, R. M.
AU - Laird, P. W.
AU - Cope, L.
AU - Herman, J. G.
AU - Shen, H.
AU - Weisenberger, D. J.
AU - Noushmehr, H.
AU - Pan, F.
AU - Triche, T.
AU - Berman, B. P.
AU - Van Den Berg, D. J.
AU - Buckley, J.
AU - Baylin, S. B.
AU - Spellman, P. T.
AU - Purdom, E.
AU - Neuvial, P.
AU - Bengtsson, H.
AU - Jakkula, L. R.
AU - Durinck, S.
AU - Han, J.
AU - Dorton, S.
AU - Marr, H.
AU - Choi, Y. G.
AU - Wang, V.
AU - Wang, N. J.
AU - Ngai, J.
AU - Conboy, J. G.
AU - Parvin, B.
AU - Feiler, H. S.
AU - Speed, T. P.
AU - Gray, J. W.
AU - Socci, N. D.
AU - Liang, Y.
AU - Taylor, B. S.
AU - Schultz, N.
AU - Borsu, L.
AU - Lash, A. E.
AU - Brennan, C.
AU - Viale, A.
AU - Sander, C.
AU - Ladanyi, M.
AU - Hoadley, K. A.
AU - Meng, S.
AU - Du, Y.
AU - Shi, Y.
AU - Li, L.
AU - Turman, Y. J.
AU - Zang, D.
AU - Helms, E. B.
AU - Balu, S.
AU - Zhou, X.
AU - Wu, J.
AU - Topal, M. D.
AU - Hayes, D. N.
AU - Perou, C. M.
AU - Wu, C. J.
AU - Shukla, S.
AU - Sivachenko, A.
AU - Jing, R.
AU - Liu, Y.
AU - Noble, M.
AU - Carter, H.
AU - Kim, D.
AU - Karchin, R.
AU - Korkola, J. E.
AU - Heiser, L. M.
AU - Cho, R. J.
AU - Hu, Z.
AU - Cerami, E.
AU - Olshen, A.
AU - Reva, B.
AU - Antipin, Y.
AU - Shen, R.
AU - Mankoo, P.
AU - Sheridan, R.
AU - Ciriello, G.
AU - Chang, W. K.
AU - Bernanke, J. A.
AU - Haussler, D.
AU - Benz, C. C.
AU - Stuart, J. M.
AU - Benz, S. C.
AU - Sanborn, J. Z.
AU - Vaske, C. J.
AU - Zhu, J.
AU - Szeto, C.
AU - Scott, G. K.
AU - Yau, C.
AU - Wilkerson, M. D.
AU - Zhang, N.
AU - Akbani, R.
AU - Baggerly, K. A.
AU - Yung, W. K.
AU - Weinstein, J. N.
AU - Shelton, T.
AU - Grimm, D.
AU - Hatfield, M.
AU - Morris, S.
AU - Yena, P.
AU - Rhodes, P.
AU - Sherman, M.
AU - Paulauskis, J.
AU - Millis, S.
AU - Kahn, A.
AU - Greene, J. M.
AU - Sfeir, R.
AU - Jensen, M. A.
AU - Chen, J.
AU - Whitmore, J.
AU - Alonso, S.
AU - Jordan, J.
AU - Chu, A.
AU - Barker, A.
AU - Compton, C.
AU - Eley, G.
AU - Ferguson, M.
AU - Fielding, P.
AU - Gerhard, D. S.
AU - Myles, R.
AU - Schaefer, C.
AU - Mills Shaw, K. R.
AU - Vaught, J.
AU - Vockley, J. B.
AU - Good, P. J.
AU - Guyer, M. S.
AU - Ozenberger, B.
AU - Peterson, J.
AU - Thomson, E.
PY - 2011/6/30
Y1 - 2011/6/30
N2 - A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.
AB - A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.
KW - Aged
KW - Carcinoma/genetics
KW - DNA Methylation
KW - Female
KW - Gene Dosage
KW - Gene Expression Profiling
KW - Gene Expression Regulation, Neoplastic
KW - Genomics
KW - Humans
KW - MicroRNAs/metabolism
KW - Middle Aged
KW - Mutation/genetics
KW - Ovarian Neoplasms/genetics
KW - RNA, Messenger/metabolism
UR - http://www.scopus.com/inward/record.url?scp=79959838081&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000292204300032&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1038/nature10166
DO - 10.1038/nature10166
M3 - Article
C2 - 21720365
SN - 0028-0836
VL - 474
SP - 609
EP - 615
JO - Nature
JF - Nature
IS - 7353
ER -